ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Antiviral Immunoglobulin Market Research Report 2026
Published Date: 2026-05-27
|
Report Code: QYRE-Auto-38B20116
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Antiviral Immunoglobulin Market Research Report 2026
BUY CHAPTERS

Global Antiviral Immunoglobulin Market Research Report 2026

Code: QYRE-Auto-38B20116
Report
2026-05-27
Pages:152
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Biotest (Germany)
Grifols (Spain)
Intas Pharmaceuticals (India)
Kedrion (Italy)
Octapharma (Switzerland)
Roche (Switzerland)
Sanofi (France)
Takeda Pharmaceutical Japan
ADMA Biologics (US)
AstraZeneca (UK/Sweden)
Bharat Serums & Vaccines (India)
Boya Bio (China)
China Biologic Products (CNBG) (China)
CSL Behring (US/Germany)
Emergent BioSolutions (US)
GC Pharma (S. Korea)
Hualan Biological (China)
Kamada (Israel)
LFB Group (France)
Regeneron (US)
Shanghai RAAS (China)
Shuanglin Bio (China)
SK Plasma (S. Korea)
Tiantan Bio (China)
Weiguang Biological (China)
Yuanda Shuyang (China)

Antiviral Immunoglobulin Market Size

The global Antiviral Immunoglobulin market was valued at US$ 11256 million in 2025 and is anticipated to reach US$ 17572 million by 2032, at a CAGR of 6.6% from 2026 to 2032.

Antiviral Immunoglobulin Market

Antiviral Immunoglobulin Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Antiviral Immunoglobulin competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Antiviral immunoglobulin refers to a class of biological medicinal products containing specific antibodies used for the prevention (prophylaxis) or treatment of viral diseases, operating on the principle of passive immunization. In 2025,global antiviral immunoglobulin production reached approximately 1,731K Kg, with an average global market price of around USD 6,500 per Kg. A factory gross profit of USD 1,950 per Kg with 30% gross margin. A single line full machine capacity production is around 25K Kg per line per year.The upstream segment is highly dependent on the global human plasma supply chain. Downstream demand is concentrated in hospitals,emergency care and research and specialty clinics. A hepatitis B-positive liver transplant recipient receives HBIG therapy following transplantation to reduce the risk of viral recurrence and graft failure. China isleading due to aggressive expansion of plasma-derived biologics manufacturing, increasing healthcare expenditure, and growing domestic demand for immunotherapy products. while US following due to advanced transplant medicine, high immunoglobulin utilization rates, strong reimbursement systems, and continuous expansion of plasma donation infrastructure.
The North American market for Antiviral Immunoglobulin is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Antiviral Immunoglobulin is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Antiviral Immunoglobulin include ADMA Biologics (US), AstraZeneca (UK/Sweden), Bharat Serums & Vaccines (India), Biotest (Germany), Boya Bio (China), China Biologic Products (CNBG) (China), CSL Behring (US/Germany), Emergent BioSolutions (US), GC Pharma (S. Korea), Grifols (Spain), etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Antiviral Immunoglobulin market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Antiviral Immunoglobulin. The Antiviral Immunoglobulin market size, estimates, and forecasts are provided in terms of sales volume (kg) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Antiviral Immunoglobulin market comprehensively. Regional market sizes by Type, by Application, by IgG Purity, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Antiviral Immunoglobulin manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Antiviral Immunoglobulin Market Report

Report Metric Details
Report Name Antiviral Immunoglobulin Market
Accounted market size in 2025 US$ 11256 million
Forecasted market size in 2032 US$ 17572 million
CAGR 6.6%
Base Year 2025
Forecasted years 2026 - 2032
Segment by Type
  • Human Plasma Derived Polyclonal
  • Hyperimmune Specific Globulin
  • Recombinant Monoclonal Antibody (mAb)
  • Animal Derived (Equine/Ovine)
  • Others
Segment by IgG Purity
  • Standard Fractionated Grade (90%–95%)
  • Clinical High Purity Grade (96%–98%)
  • Ultra Purified Specialty Grade(99%)
Segment by Therapeutic Area
  • Transplantation
  • Infectious Disease Prophylaxis
  • Immunodeficiency
  • Neurology (Autoimmune)
  • Others
by Application
  • Hospitals
  • Specialty Clinics
  • Home Care
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company ADMA Biologics (US), AstraZeneca (UK/Sweden), Bharat Serums & Vaccines (India), Biotest (Germany), Boya Bio (China), China Biologic Products (CNBG) (China), CSL Behring (US/Germany), Emergent BioSolutions (US), GC Pharma (S. Korea), Grifols (Spain), Hualan Biological (China), Intas Pharmaceuticals (India), Kamada (Israel), Kedrion (Italy), LFB Group (France), Octapharma (Switzerland), Regeneron (US), Roche (Switzerland), Sanofi (France), Shanghai RAAS (China), Shuanglin Bio (China), SK Plasma (S. Korea), Takeda Pharmaceutical (Japan), Tiantan Bio (China), Weiguang Biological (China), Yuanda Shuyang (China)
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by IgG Purity, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Antiviral Immunoglobulin manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Antiviral Immunoglobulin sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Antiviral Immunoglobulin Market growing?

Ans: The Antiviral Immunoglobulin Market witnessing a CAGR of 6.6% during the forecast period 2026-2032.

What is the Antiviral Immunoglobulin Market size in 2032?

Ans: The Antiviral Immunoglobulin Market size in 2032 will be US$ 17572 million.

Who are the main players in the Antiviral Immunoglobulin Market report?

Ans: The main players in the Antiviral Immunoglobulin Market are ADMA Biologics (US), AstraZeneca (UK/Sweden), Bharat Serums & Vaccines (India), Biotest (Germany), Boya Bio (China), China Biologic Products (CNBG) (China), CSL Behring (US/Germany), Emergent BioSolutions (US), GC Pharma (S. Korea), Grifols (Spain), Hualan Biological (China), Intas Pharmaceuticals (India), Kamada (Israel), Kedrion (Italy), LFB Group (France), Octapharma (Switzerland), Regeneron (US), Roche (Switzerland), Sanofi (France), Shanghai RAAS (China), Shuanglin Bio (China), SK Plasma (S. Korea), Takeda Pharmaceutical (Japan), Tiantan Bio (China), Weiguang Biological (China), Yuanda Shuyang (China)

What are the Application segmentation covered in the Antiviral Immunoglobulin Market report?

Ans: The Applications covered in the Antiviral Immunoglobulin Market report are Hospitals, Specialty Clinics, Home Care, Others

What are the Type segmentation covered in the Antiviral Immunoglobulin Market report?

Ans: The Types covered in the Antiviral Immunoglobulin Market report are Human Plasma Derived Polyclonal, Hyperimmune Specific Globulin, Recombinant Monoclonal Antibody (mAb), Animal Derived (Equine/Ovine), Others

1 Antiviral Immunoglobulin Market Overview
1.1 Product Definition
1.2 Antiviral Immunoglobulin by Type
1.2.1 Global Antiviral Immunoglobulin Market Value by Type: 2025 vs 2032
1.2.2 Human Plasma Derived Polyclonal
1.2.3 Hyperimmune Specific Globulin
1.2.4 Recombinant Monoclonal Antibody (mAb)
1.2.5 Animal Derived (Equine/Ovine)
1.2.6 Others
1.3 Antiviral Immunoglobulin by IgG Purity
1.3.1 Global Antiviral Immunoglobulin Market Value by IgG Purity: 2025 vs 2032
1.3.2 Standard Fractionated Grade (90%–95%)
1.3.3 Clinical High Purity Grade (96%–98%)
1.3.4 Ultra Purified Specialty Grade(99%)
1.4 Antiviral Immunoglobulin by Therapeutic Area
1.4.1 Global Antiviral Immunoglobulin Market Value by Therapeutic Area: 2025 vs 2032
1.4.2 Transplantation
1.4.3 Infectious Disease Prophylaxis
1.4.4 Immunodeficiency
1.4.5 Neurology (Autoimmune)
1.4.6 Others
1.5 Antiviral Immunoglobulin by Application
1.5.1 Global Antiviral Immunoglobulin Market Value by Application: 2025 vs 2032
1.5.2 Hospitals
1.5.3 Specialty Clinics
1.5.4 Home Care
1.5.5 Others
1.6 Global Antiviral Immunoglobulin Market Size Estimates and Forecasts
1.6.1 Global Antiviral Immunoglobulin Revenue 2021–2032
1.6.2 Global Antiviral Immunoglobulin Sales 2021–2032
1.6.3 Global Antiviral Immunoglobulin Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Antiviral Immunoglobulin Market Competition by Manufacturers
2.1 Global Antiviral Immunoglobulin Sales Market Share by Manufacturers (2021–2026)
2.2 Global Antiviral Immunoglobulin Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Antiviral Immunoglobulin Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Antiviral Immunoglobulin, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Antiviral Immunoglobulin, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Antiviral Immunoglobulin, Product Types and Applications
2.7 Global Key Manufacturers of Antiviral Immunoglobulin, Date of Entry into the Industry
2.8 Global Antiviral Immunoglobulin Market Competitive Situation and Trends
2.8.1 Global Antiviral Immunoglobulin Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Antiviral Immunoglobulin Players Market Share by Revenue
2.8.3 Global Antiviral Immunoglobulin Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Antiviral Immunoglobulin Market Scenario by Region
3.1 Global Antiviral Immunoglobulin Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Antiviral Immunoglobulin Sales by Region: 2021–2032
3.2.1 Global Antiviral Immunoglobulin Sales by Region: 2021–2026
3.2.2 Global Antiviral Immunoglobulin Sales by Region: 2027–2032
3.3 Global Antiviral Immunoglobulin Revenue by Region: 2021–2032
3.3.1 Global Antiviral Immunoglobulin Revenue by Region: 2021–2026
3.3.2 Global Antiviral Immunoglobulin Revenue by Region: 2027–2032
3.4 North America Antiviral Immunoglobulin Market Facts & Figures by Country
3.4.1 North America Antiviral Immunoglobulin Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Antiviral Immunoglobulin Sales by Country (2021–2032)
3.4.3 North America Antiviral Immunoglobulin Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antiviral Immunoglobulin Market Facts & Figures by Country
3.5.1 Europe Antiviral Immunoglobulin Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Antiviral Immunoglobulin Sales by Country (2021–2032)
3.5.3 Europe Antiviral Immunoglobulin Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antiviral Immunoglobulin Market Facts & Figures by Region
3.6.1 Asia Pacific Antiviral Immunoglobulin Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Antiviral Immunoglobulin Sales by Region (2021–2032)
3.6.3 Asia Pacific Antiviral Immunoglobulin Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Antiviral Immunoglobulin Market Facts & Figures by Country
3.7.1 Latin America Antiviral Immunoglobulin Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Antiviral Immunoglobulin Sales by Country (2021–2032)
3.7.3 Latin America Antiviral Immunoglobulin Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Antiviral Immunoglobulin Market Facts & Figures by Country
3.8.1 Middle East and Africa Antiviral Immunoglobulin Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Antiviral Immunoglobulin Sales by Country (2021–2032)
3.8.3 Middle East and Africa Antiviral Immunoglobulin Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antiviral Immunoglobulin Sales by Type (2021–2032)
4.1.1 Global Antiviral Immunoglobulin Sales by Type (2021–2026)
4.1.2 Global Antiviral Immunoglobulin Sales by Type (2027–2032)
4.1.3 Global Antiviral Immunoglobulin Sales Market Share by Type (2021–2032)
4.2 Global Antiviral Immunoglobulin Revenue by Type (2021–2032)
4.2.1 Global Antiviral Immunoglobulin Revenue by Type (2021–2026)
4.2.2 Global Antiviral Immunoglobulin Revenue by Type (2027–2032)
4.2.3 Global Antiviral Immunoglobulin Revenue Market Share by Type (2021–2032)
4.3 Global Antiviral Immunoglobulin Price by Type (2021–2032)
5 Segment by Application
5.1 Global Antiviral Immunoglobulin Sales by Application (2021–2032)
5.1.1 Global Antiviral Immunoglobulin Sales by Application (2021–2026)
5.1.2 Global Antiviral Immunoglobulin Sales by Application (2027–2032)
5.1.3 Global Antiviral Immunoglobulin Sales Market Share by Application (2021–2032)
5.2 Global Antiviral Immunoglobulin Revenue by Application (2021–2032)
5.2.1 Global Antiviral Immunoglobulin Revenue by Application (2021–2026)
5.2.2 Global Antiviral Immunoglobulin Revenue by Application (2027–2032)
5.2.3 Global Antiviral Immunoglobulin Revenue Market Share by Application (2021–2032)
5.3 Global Antiviral Immunoglobulin Price by Application (2021–2032)
6 Key Companies Profiled
6.1 ADMA Biologics (US)
6.1.1 ADMA Biologics (US) Company Information
6.1.2 ADMA Biologics (US) Description and Business Overview
6.1.3 ADMA Biologics (US) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 ADMA Biologics (US) Antiviral Immunoglobulin Product Portfolio
6.1.5 ADMA Biologics (US) Recent Developments/Updates
6.2 AstraZeneca (UK/Sweden)
6.2.1 AstraZeneca (UK/Sweden) Company Information
6.2.2 AstraZeneca (UK/Sweden) Description and Business Overview
6.2.3 AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Product Portfolio
6.2.5 AstraZeneca (UK/Sweden) Recent Developments/Updates
6.3 Bharat Serums & Vaccines (India)
6.3.1 Bharat Serums & Vaccines (India) Company Information
6.3.2 Bharat Serums & Vaccines (India) Description and Business Overview
6.3.3 Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Product Portfolio
6.3.5 Bharat Serums & Vaccines (India) Recent Developments/Updates
6.4 Biotest (Germany)
6.4.1 Biotest (Germany) Company Information
6.4.2 Biotest (Germany) Description and Business Overview
6.4.3 Biotest (Germany) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Biotest (Germany) Antiviral Immunoglobulin Product Portfolio
6.4.5 Biotest (Germany) Recent Developments/Updates
6.5 Boya Bio (China)
6.5.1 Boya Bio (China) Company Information
6.5.2 Boya Bio (China) Description and Business Overview
6.5.3 Boya Bio (China) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Boya Bio (China) Antiviral Immunoglobulin Product Portfolio
6.5.5 Boya Bio (China) Recent Developments/Updates
6.6 China Biologic Products (CNBG) (China)
6.6.1 China Biologic Products (CNBG) (China) Company Information
6.6.2 China Biologic Products (CNBG) (China) Description and Business Overview
6.6.3 China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Product Portfolio
6.6.5 China Biologic Products (CNBG) (China) Recent Developments/Updates
6.7 CSL Behring (US/Germany)
6.7.1 CSL Behring (US/Germany) Company Information
6.7.2 CSL Behring (US/Germany) Description and Business Overview
6.7.3 CSL Behring (US/Germany) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 CSL Behring (US/Germany) Antiviral Immunoglobulin Product Portfolio
6.7.5 CSL Behring (US/Germany) Recent Developments/Updates
6.8 Emergent BioSolutions (US)
6.8.1 Emergent BioSolutions (US) Company Information
6.8.2 Emergent BioSolutions (US) Description and Business Overview
6.8.3 Emergent BioSolutions (US) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Emergent BioSolutions (US) Antiviral Immunoglobulin Product Portfolio
6.8.5 Emergent BioSolutions (US) Recent Developments/Updates
6.9 GC Pharma (S. Korea)
6.9.1 GC Pharma (S. Korea) Company Information
6.9.2 GC Pharma (S. Korea) Description and Business Overview
6.9.3 GC Pharma (S. Korea) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 GC Pharma (S. Korea) Antiviral Immunoglobulin Product Portfolio
6.9.5 GC Pharma (S. Korea) Recent Developments/Updates
6.10 Grifols (Spain)
6.10.1 Grifols (Spain) Company Information
6.10.2 Grifols (Spain) Description and Business Overview
6.10.3 Grifols (Spain) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Grifols (Spain) Antiviral Immunoglobulin Product Portfolio
6.10.5 Grifols (Spain) Recent Developments/Updates
6.11 Hualan Biological (China)
6.11.1 Hualan Biological (China) Company Information
6.11.2 Hualan Biological (China) Description and Business Overview
6.11.3 Hualan Biological (China) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Hualan Biological (China) Antiviral Immunoglobulin Product Portfolio
6.11.5 Hualan Biological (China) Recent Developments/Updates
6.12 Intas Pharmaceuticals (India)
6.12.1 Intas Pharmaceuticals (India) Company Information
6.12.2 Intas Pharmaceuticals (India) Description and Business Overview
6.12.3 Intas Pharmaceuticals (India) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Intas Pharmaceuticals (India) Antiviral Immunoglobulin Product Portfolio
6.12.5 Intas Pharmaceuticals (India) Recent Developments/Updates
6.13 Kamada (Israel)
6.13.1 Kamada (Israel) Company Information
6.13.2 Kamada (Israel) Description and Business Overview
6.13.3 Kamada (Israel) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Kamada (Israel) Antiviral Immunoglobulin Product Portfolio
6.13.5 Kamada (Israel) Recent Developments/Updates
6.14 Kedrion (Italy)
6.14.1 Kedrion (Italy) Company Information
6.14.2 Kedrion (Italy) Description and Business Overview
6.14.3 Kedrion (Italy) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Kedrion (Italy) Antiviral Immunoglobulin Product Portfolio
6.14.5 Kedrion (Italy) Recent Developments/Updates
6.15 LFB Group (France)
6.15.1 LFB Group (France) Company Information
6.15.2 LFB Group (France) Description and Business Overview
6.15.3 LFB Group (France) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 LFB Group (France) Antiviral Immunoglobulin Product Portfolio
6.15.5 LFB Group (France) Recent Developments/Updates
6.16 Octapharma (Switzerland)
6.16.1 Octapharma (Switzerland) Company Information
6.16.2 Octapharma (Switzerland) Description and Business Overview
6.16.3 Octapharma (Switzerland) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Octapharma (Switzerland) Antiviral Immunoglobulin Product Portfolio
6.16.5 Octapharma (Switzerland) Recent Developments/Updates
6.17 Regeneron (US)
6.17.1 Regeneron (US) Company Information
6.17.2 Regeneron (US) Description and Business Overview
6.17.3 Regeneron (US) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Regeneron (US) Antiviral Immunoglobulin Product Portfolio
6.17.5 Regeneron (US) Recent Developments/Updates
6.18 Roche (Switzerland)
6.18.1 Roche (Switzerland) Company Information
6.18.2 Roche (Switzerland) Description and Business Overview
6.18.3 Roche (Switzerland) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Roche (Switzerland) Antiviral Immunoglobulin Product Portfolio
6.18.5 Roche (Switzerland) Recent Developments/Updates
6.19 Sanofi (France)
6.19.1 Sanofi (France) Company Information
6.19.2 Sanofi (France) Description and Business Overview
6.19.3 Sanofi (France) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Sanofi (France) Antiviral Immunoglobulin Product Portfolio
6.19.5 Sanofi (France) Recent Developments/Updates
6.20 Shanghai RAAS (China)
6.20.1 Shanghai RAAS (China) Company Information
6.20.2 Shanghai RAAS (China) Description and Business Overview
6.20.3 Shanghai RAAS (China) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.20.4 Shanghai RAAS (China) Antiviral Immunoglobulin Product Portfolio
6.20.5 Shanghai RAAS (China) Recent Developments/Updates
6.21 Shuanglin Bio (China)
6.21.1 Shuanglin Bio (China) Company Information
6.21.2 Shuanglin Bio (China) Description and Business Overview
6.21.3 Shuanglin Bio (China) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.21.4 Shuanglin Bio (China) Antiviral Immunoglobulin Product Portfolio
6.21.5 Shuanglin Bio (China) Recent Developments/Updates
6.22 SK Plasma (S. Korea)
6.22.1 SK Plasma (S. Korea) Company Information
6.22.2 SK Plasma (S. Korea) Description and Business Overview
6.22.3 SK Plasma (S. Korea) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.22.4 SK Plasma (S. Korea) Antiviral Immunoglobulin Product Portfolio
6.22.5 SK Plasma (S. Korea) Recent Developments/Updates
6.23 Takeda Pharmaceutical (Japan)
6.23.1 Takeda Pharmaceutical (Japan) Company Information
6.23.2 Takeda Pharmaceutical (Japan) Description and Business Overview
6.23.3 Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.23.4 Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Product Portfolio
6.23.5 Takeda Pharmaceutical (Japan) Recent Developments/Updates
6.24 Tiantan Bio (China)
6.24.1 Tiantan Bio (China) Company Information
6.24.2 Tiantan Bio (China) Description and Business Overview
6.24.3 Tiantan Bio (China) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.24.4 Tiantan Bio (China) Antiviral Immunoglobulin Product Portfolio
6.24.5 Tiantan Bio (China) Recent Developments/Updates
6.25 Weiguang Biological (China)
6.25.1 Weiguang Biological (China) Company Information
6.25.2 Weiguang Biological (China) Description and Business Overview
6.25.3 Weiguang Biological (China) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.25.4 Weiguang Biological (China) Antiviral Immunoglobulin Product Portfolio
6.25.5 Weiguang Biological (China) Recent Developments/Updates
6.26 Yuanda Shuyang (China)
6.26.1 Yuanda Shuyang (China) Company Information
6.26.2 Yuanda Shuyang (China) Description and Business Overview
6.26.3 Yuanda Shuyang (China) Antiviral Immunoglobulin Sales, Revenue, and Gross Margin (2021–2026)
6.26.4 Yuanda Shuyang (China) Antiviral Immunoglobulin Product Portfolio
6.26.5 Yuanda Shuyang (China) Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antiviral Immunoglobulin Industry Chain Analysis
7.2 Antiviral Immunoglobulin Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antiviral Immunoglobulin Production Mode & Process Analysis
7.4 Antiviral Immunoglobulin Sales and Marketing
7.4.1 Antiviral Immunoglobulin Sales Channels
7.4.2 Antiviral Immunoglobulin Distributors
7.5 Antiviral Immunoglobulin Customer Analysis
8 Antiviral Immunoglobulin Market Dynamics
8.1 Antiviral Immunoglobulin Industry Trends
8.2 Antiviral Immunoglobulin Market Drivers
8.3 Antiviral Immunoglobulin Market Challenges
8.4 Antiviral Immunoglobulin Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Biotest (Germany)
Grifols (Spain)
Intas Pharmaceuticals (India)
Kedrion (Italy)
Octapharma (Switzerland)
Roche (Switzerland)
Sanofi (France)
Takeda Pharmaceutical Japan
ADMA Biologics (US)
AstraZeneca (UK/Sweden)
Bharat Serums & Vaccines (India)
Boya Bio (China)
China Biologic Products (CNBG) (China)
CSL Behring (US/Germany)
Emergent BioSolutions (US)
GC Pharma (S. Korea)
Hualan Biological (China)
Kamada (Israel)
LFB Group (France)
Regeneron (US)
Shanghai RAAS (China)
Shuanglin Bio (China)
SK Plasma (S. Korea)
Tiantan Bio (China)
Weiguang Biological (China)
Yuanda Shuyang (China)
List of Tables
 Table 1. Global Antiviral Immunoglobulin Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Antiviral Immunoglobulin Market Value by IgG Purity (US$ Million), 2025 vs 2032
 Table 3. Global Antiviral Immunoglobulin Market Value by Therapeutic Area (US$ Million), 2025 vs 2032
 Table 4. Global Antiviral Immunoglobulin Market Value by Application (US$ Million), 2025 vs 2032
 Table 5. Global Antiviral Immunoglobulin Market Competitive Situation by Manufacturers in 2025
 Table 6. Global Antiviral Immunoglobulin Sales (kg) of Key Manufacturers (2021–2026)
 Table 7. Global Antiviral Immunoglobulin Sales Market Share by Manufacturers (2021–2026)
 Table 8. Global Antiviral Immunoglobulin Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 9. Global Antiviral Immunoglobulin Revenue Share by Manufacturers (2021–2026)
 Table 10. Global Market Antiviral Immunoglobulin Average Price (US$/kg) of Key Manufacturers (2021–2026)
 Table 11. Global Key Players of Antiviral Immunoglobulin, Industry Ranking, 2023 vs 2024 vs 2025
 Table 12. Global Key Manufacturers of Antiviral Immunoglobulin, Manufacturing Sites and Headquarters
 Table 13. Global Key Manufacturers of Antiviral Immunoglobulin, Product Types and Applications
 Table 14. Global Key Manufacturers of Antiviral Immunoglobulin, Date of Entry into the Industry
 Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 16. Global Antiviral Immunoglobulin Companies by Tier (Tier 1, Tier 2, Tier 3), based on Antiviral Immunoglobulin Revenue, 2025
 Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 18. Global Antiviral Immunoglobulin Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 19. Global Antiviral Immunoglobulin Sales by Region (kg), 2021–2026
 Table 20. Global Antiviral Immunoglobulin Sales Market Share by Region (2021–2026)
 Table 21. Global Antiviral Immunoglobulin Sales by Region (kg), 2027–2032
 Table 22. Global Antiviral Immunoglobulin Sales Market Share by Region (2027–2032)
 Table 23. Global Antiviral Immunoglobulin Revenue by Region (US$ Million), 2021–2026
 Table 24. Global Antiviral Immunoglobulin Revenue Market Share by Region (2021–2026)
 Table 25. Global Antiviral Immunoglobulin Revenue by Region (US$ Million), 2027–2032
 Table 26. Global Antiviral Immunoglobulin Revenue Market Share by Region (2027–2032)
 Table 27. North America Antiviral Immunoglobulin Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 28. North America Antiviral Immunoglobulin Sales by Country (kg), 2021–2026
 Table 29. North America Antiviral Immunoglobulin Sales by Country (kg), 2027–2032
 Table 30. North America Antiviral Immunoglobulin Revenue by Country (US$ Million), 2021–2026
 Table 31. North America Antiviral Immunoglobulin Revenue by Country (US$ Million), 2027–2032
 Table 32. Europe Antiviral Immunoglobulin Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 33. Europe Antiviral Immunoglobulin Sales by Country (kg), 2021–2026
 Table 34. Europe Antiviral Immunoglobulin Sales by Country (kg), 2027–2032
 Table 35. Europe Antiviral Immunoglobulin Revenue by Country (US$ Million), 2021–2026
 Table 36. Europe Antiviral Immunoglobulin Revenue by Country (US$ Million), 2027–2032
 Table 37. Asia Pacific Antiviral Immunoglobulin Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 38. Asia Pacific Antiviral Immunoglobulin Sales by Region (kg), 2021–2026
 Table 39. Asia Pacific Antiviral Immunoglobulin Sales by Region (kg), 2027–2032
 Table 40. Asia Pacific Antiviral Immunoglobulin Revenue by Region (US$ Million), 2021–2026
 Table 41. Asia Pacific Antiviral Immunoglobulin Revenue by Region (US$ Million), 2027–2032
 Table 42. Latin America Antiviral Immunoglobulin Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 43. Latin America Antiviral Immunoglobulin Sales by Country (kg), 2021–2026
 Table 44. Latin America Antiviral Immunoglobulin Sales by Country (kg), 2027–2032
 Table 45. Latin America Antiviral Immunoglobulin Revenue by Country (US$ Million), 2021–2026
 Table 46. Latin America Antiviral Immunoglobulin Revenue by Country (US$ Million), 2027–2032
 Table 47. Middle East and Africa Antiviral Immunoglobulin Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 48. Middle East and Africa Antiviral Immunoglobulin Sales by Country (kg), 2021–2026
 Table 49. Middle East and Africa Antiviral Immunoglobulin Sales by Country (kg), 2027–2032
 Table 50. Middle East and Africa Antiviral Immunoglobulin Revenue by Country (US$ Million), 2021–2026
 Table 51. Middle East and Africa Antiviral Immunoglobulin Revenue by Country (US$ Million), 2027–2032
 Table 52. Global Antiviral Immunoglobulin Sales (kg) by Type (2021–2026)
 Table 53. Global Antiviral Immunoglobulin Sales (kg) by Type (2027–2032)
 Table 54. Global Antiviral Immunoglobulin Sales Market Share by Type (2021–2026)
 Table 55. Global Antiviral Immunoglobulin Sales Market Share by Type (2027–2032)
 Table 56. Global Antiviral Immunoglobulin Revenue (US$ Million) by Type (2021–2026)
 Table 57. Global Antiviral Immunoglobulin Revenue (US$ Million) by Type (2027–2032)
 Table 58. Global Antiviral Immunoglobulin Revenue Market Share by Type (2021–2026)
 Table 59. Global Antiviral Immunoglobulin Revenue Market Share by Type (2027–2032)
 Table 60. Global Antiviral Immunoglobulin Price (US$/kg) by Type (2021–2026)
 Table 61. Global Antiviral Immunoglobulin Price (US$/kg) by Type (2027–2032)
 Table 62. Global Antiviral Immunoglobulin Sales (kg) by Application (2021–2026)
 Table 63. Global Antiviral Immunoglobulin Sales (kg) by Application (2027–2032)
 Table 64. Global Antiviral Immunoglobulin Sales Market Share by Application (2021–2026)
 Table 65. Global Antiviral Immunoglobulin Sales Market Share by Application (2027–2032)
 Table 66. Global Antiviral Immunoglobulin Revenue (US$ Million) by Application (2021–2026)
 Table 67. Global Antiviral Immunoglobulin Revenue (US$ Million) by Application (2027–2032)
 Table 68. Global Antiviral Immunoglobulin Revenue Market Share by Application (2021–2026)
 Table 69. Global Antiviral Immunoglobulin Revenue Market Share by Application (2027–2032)
 Table 70. Global Antiviral Immunoglobulin Price (US$/kg) by Application (2021–2026)
 Table 71. Global Antiviral Immunoglobulin Price (US$/kg) by Application (2027–2032)
 Table 72. ADMA Biologics (US) Company Information
 Table 73. ADMA Biologics (US) Description and Business Overview
 Table 74. ADMA Biologics (US) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 75. ADMA Biologics (US) Antiviral Immunoglobulin Product
 Table 76. ADMA Biologics (US) Recent Developments/Updates
 Table 77. AstraZeneca (UK/Sweden) Company Information
 Table 78. AstraZeneca (UK/Sweden) Description and Business Overview
 Table 79. AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 80. AstraZeneca (UK/Sweden) Antiviral Immunoglobulin Product
 Table 81. AstraZeneca (UK/Sweden) Recent Developments/Updates
 Table 82. Bharat Serums & Vaccines (India) Company Information
 Table 83. Bharat Serums & Vaccines (India) Description and Business Overview
 Table 84. Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 85. Bharat Serums & Vaccines (India) Antiviral Immunoglobulin Product
 Table 86. Bharat Serums & Vaccines (India) Recent Developments/Updates
 Table 87. Biotest (Germany) Company Information
 Table 88. Biotest (Germany) Description and Business Overview
 Table 89. Biotest (Germany) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 90. Biotest (Germany) Antiviral Immunoglobulin Product
 Table 91. Biotest (Germany) Recent Developments/Updates
 Table 92. Boya Bio (China) Company Information
 Table 93. Boya Bio (China) Description and Business Overview
 Table 94. Boya Bio (China) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 95. Boya Bio (China) Antiviral Immunoglobulin Product
 Table 96. Boya Bio (China) Recent Developments/Updates
 Table 97. China Biologic Products (CNBG) (China) Company Information
 Table 98. China Biologic Products (CNBG) (China) Description and Business Overview
 Table 99. China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 100. China Biologic Products (CNBG) (China) Antiviral Immunoglobulin Product
 Table 101. China Biologic Products (CNBG) (China) Recent Developments/Updates
 Table 102. CSL Behring (US/Germany) Company Information
 Table 103. CSL Behring (US/Germany) Description and Business Overview
 Table 104. CSL Behring (US/Germany) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 105. CSL Behring (US/Germany) Antiviral Immunoglobulin Product
 Table 106. CSL Behring (US/Germany) Recent Developments/Updates
 Table 107. Emergent BioSolutions (US) Company Information
 Table 108. Emergent BioSolutions (US) Description and Business Overview
 Table 109. Emergent BioSolutions (US) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 110. Emergent BioSolutions (US) Antiviral Immunoglobulin Product
 Table 111. Emergent BioSolutions (US) Recent Developments/Updates
 Table 112. GC Pharma (S. Korea) Company Information
 Table 113. GC Pharma (S. Korea) Description and Business Overview
 Table 114. GC Pharma (S. Korea) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 115. GC Pharma (S. Korea) Antiviral Immunoglobulin Product
 Table 116. GC Pharma (S. Korea) Recent Developments/Updates
 Table 117. Grifols (Spain) Company Information
 Table 118. Grifols (Spain) Description and Business Overview
 Table 119. Grifols (Spain) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 120. Grifols (Spain) Antiviral Immunoglobulin Product
 Table 121. Grifols (Spain) Recent Developments/Updates
 Table 122. Hualan Biological (China) Company Information
 Table 123. Hualan Biological (China) Description and Business Overview
 Table 124. Hualan Biological (China) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 125. Hualan Biological (China) Antiviral Immunoglobulin Product
 Table 126. Hualan Biological (China) Recent Developments/Updates
 Table 127. Intas Pharmaceuticals (India) Company Information
 Table 128. Intas Pharmaceuticals (India) Description and Business Overview
 Table 129. Intas Pharmaceuticals (India) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 130. Intas Pharmaceuticals (India) Antiviral Immunoglobulin Product
 Table 131. Intas Pharmaceuticals (India) Recent Developments/Updates
 Table 132. Kamada (Israel) Company Information
 Table 133. Kamada (Israel) Description and Business Overview
 Table 134. Kamada (Israel) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 135. Kamada (Israel) Antiviral Immunoglobulin Product
 Table 136. Kamada (Israel) Recent Developments/Updates
 Table 137. Kedrion (Italy) Company Information
 Table 138. Kedrion (Italy) Description and Business Overview
 Table 139. Kedrion (Italy) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 140. Kedrion (Italy) Antiviral Immunoglobulin Product
 Table 141. Kedrion (Italy) Recent Developments/Updates
 Table 142. LFB Group (France) Company Information
 Table 143. LFB Group (France) Description and Business Overview
 Table 144. LFB Group (France) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 145. LFB Group (France) Antiviral Immunoglobulin Product
 Table 146. LFB Group (France) Recent Developments/Updates
 Table 147. Octapharma (Switzerland) Company Information
 Table 148. Octapharma (Switzerland) Description and Business Overview
 Table 149. Octapharma (Switzerland) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 150. Octapharma (Switzerland) Antiviral Immunoglobulin Product
 Table 151. Octapharma (Switzerland) Recent Developments/Updates
 Table 152. Regeneron (US) Company Information
 Table 153. Regeneron (US) Description and Business Overview
 Table 154. Regeneron (US) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 155. Regeneron (US) Antiviral Immunoglobulin Product
 Table 156. Regeneron (US) Recent Developments/Updates
 Table 157. Roche (Switzerland) Company Information
 Table 158. Roche (Switzerland) Description and Business Overview
 Table 159. Roche (Switzerland) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 160. Roche (Switzerland) Antiviral Immunoglobulin Product
 Table 161. Roche (Switzerland) Recent Developments/Updates
 Table 162. Sanofi (France) Company Information
 Table 163. Sanofi (France) Description and Business Overview
 Table 164. Sanofi (France) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 165. Sanofi (France) Antiviral Immunoglobulin Product
 Table 166. Sanofi (France) Recent Developments/Updates
 Table 167. Shanghai RAAS (China) Company Information
 Table 168. Shanghai RAAS (China) Description and Business Overview
 Table 169. Shanghai RAAS (China) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 170. Shanghai RAAS (China) Antiviral Immunoglobulin Product
 Table 171. Shanghai RAAS (China) Recent Developments/Updates
 Table 172. Shuanglin Bio (China) Company Information
 Table 173. Shuanglin Bio (China) Description and Business Overview
 Table 174. Shuanglin Bio (China) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 175. Shuanglin Bio (China) Antiviral Immunoglobulin Product
 Table 176. Shuanglin Bio (China) Recent Developments/Updates
 Table 177. SK Plasma (S. Korea) Company Information
 Table 178. SK Plasma (S. Korea) Description and Business Overview
 Table 179. SK Plasma (S. Korea) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 180. SK Plasma (S. Korea) Antiviral Immunoglobulin Product
 Table 181. SK Plasma (S. Korea) Recent Developments/Updates
 Table 182. Takeda Pharmaceutical (Japan) Company Information
 Table 183. Takeda Pharmaceutical (Japan) Description and Business Overview
 Table 184. Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 185. Takeda Pharmaceutical (Japan) Antiviral Immunoglobulin Product
 Table 186. Takeda Pharmaceutical (Japan) Recent Developments/Updates
 Table 187. Tiantan Bio (China) Company Information
 Table 188. Tiantan Bio (China) Description and Business Overview
 Table 189. Tiantan Bio (China) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 190. Tiantan Bio (China) Antiviral Immunoglobulin Product
 Table 191. Tiantan Bio (China) Recent Developments/Updates
 Table 192. Weiguang Biological (China) Company Information
 Table 193. Weiguang Biological (China) Description and Business Overview
 Table 194. Weiguang Biological (China) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 195. Weiguang Biological (China) Antiviral Immunoglobulin Product
 Table 196. Weiguang Biological (China) Recent Developments/Updates
 Table 197. Yuanda Shuyang (China) Company Information
 Table 198. Yuanda Shuyang (China) Description and Business Overview
 Table 199. Yuanda Shuyang (China) Antiviral Immunoglobulin Sales (kg), Revenue (US$ Million), Price (US$/kg), and Gross Margin (2021–2026)
 Table 200. Yuanda Shuyang (China) Antiviral Immunoglobulin Product
 Table 201. Yuanda Shuyang (China) Recent Developments/Updates
 Table 202. Key Raw Materials Lists
 Table 203. Raw Materials Key Suppliers Lists
 Table 204. Antiviral Immunoglobulin Distributors List
 Table 205. Antiviral Immunoglobulin Customers List
 Table 206. Antiviral Immunoglobulin Market Trends
 Table 207. Antiviral Immunoglobulin Market Drivers
 Table 208. Antiviral Immunoglobulin Market Challenges
 Table 209. Antiviral Immunoglobulin Market Restraints
 Table 210. Research Programs/Design for This Report
 Table 211. Key Data Information from Secondary Sources
 Table 212. Key Data Information from Primary Sources
 Table 213. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Antiviral Immunoglobulin
 Figure 2. Global Antiviral Immunoglobulin Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Antiviral Immunoglobulin Market Share by Type: 2025 & 2032
 Figure 4. Human Plasma Derived Polyclonal Product Picture
 Figure 5. Hyperimmune Specific Globulin Product Picture
 Figure 6. Recombinant Monoclonal Antibody (mAb) Product Picture
 Figure 7. Animal Derived (Equine/Ovine) Product Picture
 Figure 8. Others Product Picture
 Figure 9. Global Antiviral Immunoglobulin Market Value by IgG Purity (US$ Million), 2021–2032
 Figure 10. Global Antiviral Immunoglobulin Market Share by IgG Purity: 2025 vs 2032
 Figure 11. Standard Fractionated Grade (90%–95%) Product Picture
 Figure 12. Clinical High Purity Grade (96%–98%) Product Picture
 Figure 13. Ultra Purified Specialty Grade(99%) Product Picture
 Figure 14. Global Antiviral Immunoglobulin Market Value by Therapeutic Area (US$ Million), 2021–2032
 Figure 15. Global Antiviral Immunoglobulin Market Share by Therapeutic Area: 2025 vs 2032
 Figure 16. Transplantation Product Picture
 Figure 17. Infectious Disease Prophylaxis Product Picture
 Figure 18. Immunodeficiency Product Picture
 Figure 19. Neurology (Autoimmune) Product Picture
 Figure 20. Others Product Picture
 Figure 21. Global Antiviral Immunoglobulin Market Value by Application (US$ Million), 2021–2032
 Figure 22. Global Antiviral Immunoglobulin Market Share by Application: 2025 & 2032
 Figure 23. Hospitals
 Figure 24. Specialty Clinics
 Figure 25. Home Care
 Figure 26. Others
 Figure 27. Global Antiviral Immunoglobulin Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 28. Global Antiviral Immunoglobulin Market Size (US$ Million), 2021–2032
 Figure 29. Global Antiviral Immunoglobulin Sales (kg), 2021–2032
 Figure 30. Global Antiviral Immunoglobulin Average Price (US$/kg), 2021–2032
 Figure 31. Antiviral Immunoglobulin Report Years Considered
 Figure 32. Antiviral Immunoglobulin Sales Share by Manufacturers in 2025
 Figure 33. Global Antiviral Immunoglobulin Revenue Share by Manufacturers in 2025
 Figure 34. Top 5 and Top 10 Global Antiviral Immunoglobulin Players: Market Share by Revenue in Antiviral Immunoglobulin in 2025
 Figure 35. Antiviral Immunoglobulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 36. Global Antiviral Immunoglobulin Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 37. North America Antiviral Immunoglobulin Sales Market Share by Country (2021–2032)
 Figure 38. North America Antiviral Immunoglobulin Revenue Market Share by Country (2021–2032)
 Figure 39. United States Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Canada Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Europe Antiviral Immunoglobulin Sales Market Share by Country (2021–2032)
 Figure 42. Europe Antiviral Immunoglobulin Revenue Market Share by Country (2021–2032)
 Figure 43. Germany Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. France Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. U.K. Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Italy Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Russia Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Asia Pacific Antiviral Immunoglobulin Sales Market Share by Region (2021–2032)
 Figure 49. Asia Pacific Antiviral Immunoglobulin Revenue Market Share by Region (2021–2032)
 Figure 50. China Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Japan Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. South Korea Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. India Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. Australia Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. China Taiwan Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 56. Southeast Asia Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 57. Latin America Antiviral Immunoglobulin Sales Market Share by Country (2021–2032)
 Figure 58. Latin America Antiviral Immunoglobulin Revenue Market Share by Country (2021–2032)
 Figure 59. Mexico Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 60. Brazil Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 61. Argentina Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 62. Colombia Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 63. Middle East and Africa Antiviral Immunoglobulin Sales Market Share by Country (2021–2032)
 Figure 64. Middle East and Africa Antiviral Immunoglobulin Revenue Market Share by Country (2021–2032)
 Figure 65. Turkey Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 66. Saudi Arabia Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 67. UAE Antiviral Immunoglobulin Revenue Growth Rate (US$ Million), 2021–2032
 Figure 68. Global Sales Market Share of Antiviral Immunoglobulin by Type (2021–2032)
 Figure 69. Global Revenue Market Share of Antiviral Immunoglobulin by Type (2021–2032)
 Figure 70. Global Antiviral Immunoglobulin Price (US$/kg) by Type (2021–2032)
 Figure 71. Global Sales Market Share of Antiviral Immunoglobulin by Application (2021–2032)
 Figure 72. Global Revenue Market Share of Antiviral Immunoglobulin by Application (2021–2032)
 Figure 73. Global Antiviral Immunoglobulin Price (US$/kg) by Application (2021–2032)
 Figure 74. Antiviral Immunoglobulin Value Chain
 Figure 75. Channels of Distribution (Direct Vs Distribution)
 Figure 76. Bottom-up and Top-down Approaches for This Report
 Figure 77. Data Triangulation
 Figure 78. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions